The Joint Blog

JULY 12, 2019

The crop will be divided between high THC and high CBD varieties with “recent interest (in CBD) as a potential medicine for a number of medical conditions,” NIDA said. Last year, a CBD-based drug was approved by federal regulators for two rare seizure disorders and researchers are pursuing research on it for other conditions.

DEA 44

DEA Marijuana THC CBD 44

The Joint Blog

AUGUST 5, 2019

The crop will be divided between high THC and high CBD varieties with “recent interest (in CBD) as a potential medicine for a number of medical conditions,” NIDA said. Last year, a CBD-based drug was approved by federal regulators for two rare seizure disorders and researchers are pursuing research on it for other conditions.

DEA 38

DEA Marijuana THC CBD 38

PrestoDoctor

JANUARY 14, 2020

The physician will conduct an evaluation to determine if your medical condition can improve with marijuana use. The physician may review a list of qualifying conditions. Other states have a list of conditions that the patients must meet to get an MMJ. Oklahoma does not have a specific list of conditions to get an MMJ.

Marijuana 52

Marijuana Patients Conditions Programs 52

PrestoDoctor

JANUARY 14, 2020

The physician will conduct an evaluation to determine if your medical condition can improve with marijuana use. The physician may review a list of qualifying conditions. Other states have a list of conditions that the patients must meet to get an MMJ. Oklahoma does not have a specific list of conditions to get an MMJ.

Marijuana 52

Marijuana Patients Conditions Programs 52

PrestoDoctor

FEBRUARY 6, 2023

The physician will conduct an evaluation to determine if your medical condition can improve with marijuana use. Oklahoma does not have a specific list of conditions to get a MMJ recommendation. Other states have a list of qualifying conditions that the patients must meet to get an MMJ. Will I Be On a List? Contact us today.

Marijuana 52

Marijuana Patients Conditions Access 52

Cannabis Law Report

SEPTEMBER 23, 2019

27 There is moderate evidence for the use of cannabinoids for sleep and limited evidence for use in psychiatric conditions, such as post-traumatic stress disorder, depression, anxiety, and psychosis; appetite stimulation and weight gain; and no evidence for cancer treatment. Approval for research expands beyond institutional review boards.

Cannabinoids 40

Cannabinoids Marijuana Research and Development Access 40

Canna Law Blog

JANUARY 8, 2025

cannabis community awaits the resumption of the DEA’s administrative law hearing on rescheduling marijuana later this month, this blog will take a glimpse at the ever-dynamic global landscape of cannabis policy. Ukraine legalized medical marijuana for specific qualifying conditions , marking a major health policy milestone.

Law 128

Law Programs Cultivation Hemp 128

Canna Law Blog

JUNE 13, 2023

Drug Enforcement Administration (DEA) to implement and enforce the relevant provisions of the Controlled Substances Import and Export Act which makes it a crime to bring controlled substances into the country without a proper license. CBP coordinates with a wide range of partner government agencies (e.g., FDA, EPA, DOT, ATF, CPSC, etc.)

DEA 97

DEA Marijuana Hemp Concentrates 97

Canna Law Blog

AUGUST 16, 2022

Today, many states have medical cannabis programs and the Food and Drug Administration has approved some cannabinoid-based drugs for certain conditions. As a refresher, the Drug Enforcement Administration (DEA) conducts the licensing process that enables researchers to gain access to cannabis product.

DEA 98

DEA Access Cannabinoids Cannabis 98

Nature's Way Medicine

FEBRUARY 12, 2021

The DEA would be mandated to approve applications for manufacturers to produce marijuana-derived, FDA-approved drugs. Many patients are having trouble reaching dispensaries from remote areas of the state and there are fewer qualified conditions for allowing patients to use marijuana. That’s it for this week.

Research and Development 97

Research and Development Patients CBD Cannabis 97

Canna Law Blog

JULY 14, 2023

But, there’s a huge controversy about whether it can be controlled, with agencies like the DEA saying it is. For now, stay tuned to the Canna Law Blog for more updates on FDA and FTC cannabinoid policies and delta-8 products. You can read more about that issue here or here.

Packaging 98

Packaging Food Edibles THC 98

Canna Law Blog

NOVEMBER 27, 2021

So according to the DEA, its abuse potential is high and it has no medical use. Also, according to the DEA, “the history of human experience probably goes back several hundred years since DMT usage is associated with a number of religious practices and rituals.” This research—as with psilocybin, MDMA, ketamine, ibogaine etc.—is

Therapy 98

Therapy Clinical Trials DEA Microdosing 98

Canna Law Blog

NOVEMBER 21, 2021

Assuming MDMA is approved to treat certain conditions — and in our view, this is a “when”, not an “if” — it will be another regulated drug that can be administered by physicians in certain conditions. With that all in mind, let’s return to what the regulated market will look like.

Decriminalization 98

Decriminalization DEA Conditions Legalization 98

Canna Law Blog

NOVEMBER 16, 2021

As to the permit itself, there are conditions on its receipt. The enforcement role moves from DEA to ATF. Also, rules around changes of ownership of these permits don’t look too onerous (yet).

DEA 98

DEA Business Banking Food 98

Canna Law Blog

MARCH 4, 2020

Similar to ketamine, psilocybin has shown great promise in clinical trials for helping to effectively treat depression and PTSD (and we’ve written about psilocybin several times on this blog, including here and here ). Failure to follow these very specific legal directives can lead to immediate criminal liability under federal law.

Legalization 61

Legalization Therapy Chronic Pain DEA 61

Canna Law Blog

MARCH 21, 2022

To impose a hemp moratorium, a county must simply declare a state of emergency related to cannabis and notify the Oregon Department of Agriculture ( ODA ) of the declaration and request that the ODA deny issuance of grower licenses in order to alleviate the conditions giving rise to the declaration. In 2020, the U.S.

Hemp 98

Hemp DEA Conditions Agriculture 98

Canna Law Blog

JULY 2, 2022

The DEA recently stated that cannabis seeds containing less than 0.3% d9-THC are not controlled substances regardless of the THC content of the mature plant, but it is not yet clear whether the DEA’s statement will affect the USDA’s prohibition. delta-9-THC). the red and blue portions).

Extraction 98

Extraction Strains Conditions Cannabis 98

NewsMunchies

MAY 20, 2021

This action by the DEA means researchers will be able to study marijuana from more than one grower. To the extent these MOAs are finalized, DEA anticipates issuing DEA registrations to these manufacturers. Rate this blog post. million for Ole Miss to grow so it can be doled out in grams to scientists.

DEA 98

DEA Chronic Pain Terpenes Packaging 98

Alchimia

APRIL 17, 2018

If we take a look at the beneficial properties of CBD , its multiple effects seem very promising to treat a large number of common conditions and/or symptoms on dogs and cats. The post Dogs, cats and CBD: Cannabis and pets appeared first on Alchimia blog. Let’s see some of them: CBD for dogs. Sulcova, P.

Pets 75

Pets CBD Cannabinoids Terpenes 75

Cannabis Law Report

JULY 12, 2019

31) The United States DEA has stated that small amounts of other cannabinoids will also occur in all cannabis extracts, even those that purport to be CBD only – unless synthesized de novo, CBD isolate will always contain small amounts of THC when extracted from a plant. 32: United States DEA. September 2004. 31: Gero Leson et al.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

Canna Law Blog

NOVEMBER 6, 2021

The following year, President Richard Nixon declared drug abuse public enemy number one, and in 1973, he formed the Drug Enforcement Administration (DEA). The DEA limits how much psilocybin can be produced annually, which drives up costs, and the agency imposes other unnecessary burdens on researchers.

Clinical Trials 98

Clinical Trials DEA Research and Development Therapy 98